Meloxicam efficacy and safety in treatment of pain syndromes of different localization according to domestic studies

More than 500 million people worldwide suffer from osteoarthritis (OA). Neck and low back pain (LBP) is one of the most common reasons for visiting a general practitioner to receive primary medical care in different countries. The prevalence of chronic LBP varies from 4% to 20%, and increases linearly from the third decade to 60 years, and stabilizes in the seventh decade of life. According to the latest published clinical guidelines of the Russian Association for the Study of Pain, nonsteroidal anti-inflammatory drugs (NSAIDs) are used in minimally effective doses and a short course to relieve acute musculoskeletal pain. The ratio of the NSAIDs activity associated with cyclooxygenase (COX) – COX-1 / COX-2 – inhibition allows us to evaluate their potential toxicity. The smaller this value, the more selective the drug is against COX-2, and the less toxic it is. Meloxicam belongs to the predominantly selective COX-2 inhibitors. In the Russian market, meloxicam of domestic production - Amelotex® is widely prescribed. Several studies have shown the high efficacy and safety of meloxicam in the treatment of pain syndromes with different localizations (LBP, neck pain of vertebrogenic nature, OA, etc.), it can be recommended for elderly patients, patients with comorbid diseases such as arterial hypertension (AH), diabetes mellitus, gastrointestinal tract pathology. Meloxicam has a good efficacy and safety profile, a pronounced symptom-modifying effect.

1. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020 Nov 28;396(10264):1711-2. doi: 10.1016/S0140-6736(20)32230-3. Epub 2020 Nov 4.

2. Jordan KP, Kadam UT, Hayward R, et al. Annual consultation prevalence of regional musculoskeletal problems in primary care: An observational study. BMC Musculoskelet Disord. 2010 Jul 2;11:144. doi: 10.1186/1471-2474-11-144

3. Corp N, Mansell G, Stynes S, et al. Evidence-based treatment recommendations for neck and low back pain across Europe: A systematic review of guidelines. Eur J Pain. 2021 Feb;25(2):275-95. doi: 10.1002/ejp.1679. Epub 2020 Nov 12.

4. Farra FD, Risio RG, Vismara L, Bergna A. Effectiveness of osteopathic interventions in chronic non-specific low back pain: A systematic review and meta-analysis. Complement Ther Med. 2021 Jan;56:102616. doi: 10.1016/j.ctim.2020.102616. Epub 2020 Nov 13.

5. Karateev AE, Nasonov EL, Ivashkin VT, et al.; Association of Rheumatologists of Russia, Russian Society for the Study of Pain, Russian Gastroenterology Association, Russian Scientific Medical Society of Therapists, Association of Traumatologists and Orthopedists of Russia, Russian Association of Palliative Medicine. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl.1):1-29. doi: 10.14412/1995-4484-2018-1-29 (In Russ.).

6. Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of oral non-selective non-steroidal antiinflammatory drugs in osteoarthritis: what does the literature say? Drug Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007/s40266-019-00660-1

7. Gore M, Tai KS, Sadosky A, et al. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012 Sep;12(7):550-60. doi: 10.1111/j.1533-2500.2012.00532.x. Epub 2012 Feb 5.

8. Kingsbury SR, Gross HJ, Isherwood G, Conaghan PG. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. Rheumatology (Oxford). 2014 May;53(5):937-47. doi: 10.1093/rheumatology/ket463. Epub 2014 Jan 30.

9. Parfenov VA, Yakhno NN, Kukushkin ML, et al. Acute nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4-11. doi: 10.14412/2074-2711-2018-2-4-11 (In Russ.).

10. Parfenov VA, Yakhno NN, Davydov OS, et al. Chronic nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(Suppl. 2):7-16. doi: 10.14412/2074-2711-2019-2S-7-16 (In Russ.).

11. Karateev AE, Nasonov EN. Meloxicam in Russia: 20 years together. Terapevticheskiy arkhiv = Therapevtic Archive. 2016;88(12):149-58. doi: 10.17116/terarkh20168812149-158 (In Russ.).

12. Beaudart C, Lengele L, Leclercq V, et al. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020 Dec;80(18):1947-59. doi: 10.1007/s40265-020-01423-8

13. Osani MC, Vaysbrot EE, Zhou M, et al. Duration of symptom relief and early trajectory of adverse events for oral nonsteroidal antiinflammatory drugs in knee osteoarthritis: a systematic review and meta-analysis. Arthritis Care Res. 2020 May;72(5):641-51. doi: 10.1002/acr.23884. Epub 2020 Apr 14.

14. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020 Oct;180:114147. doi: 10.1016/j.bcp.2020.114147. Epub 2020 Jul 10.

15. Davis А, Robson J. The dangers of NSAIDs: look both ways. Br J Gen Pract. 2016 Apr;66(645):172-3. doi: 10.3399/bjgp16X684433

16. Gore M, Sadosky A, Leslie DL, et al. Therapy switching, augmentation, and discontinuation in patients with osteoarthritis and chronic low back pain. Pain Pract. 2012 Jul;12(6):457-68. doi: 10.1111/j.1533-2500.2011.00524.x. Epub 2012 Jan 9.

17. Meloxicam. Instructions for the use of the drug. Available from: https://www.rlsnet.ru/mnn_index_id_2229.htm (accessed 02.10.2021) (In Russ.).

18. Zonova EV, Karateev AE. A sound approach to choosing nonsteroidal anti-inflammatory drugs for osteoarthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(4):47-53. doi: 10/14412/1996-7012-2018-4-47-53 (In Russ.).

19. Khalil NY, Aldosari KF. Meloxicam. Profiles Drug Subst Excip Relat Methodol. 2020;45:159-97. doi: 10.1016/bs.podrm.2019.10.006. Epub 2019 Dec 12.

20. Setyawan D, Dewi MY, Isadiartuti D. Ternary solid dispersion to improve solubility and dissolution of meloxicam. J Basic Clin Physiol Pharmacol. 2019 Dec 14;30(6):/j/jbcpp.2019.30.issue-6/jbcpp-2019-0244/jbcpp-2019-0244.xml. doi: 10.1515/jbcpp-2019-0244

21. Zhang X, Xiao Y, Huang Z, et al. Smart phase transformation system based on lyotropic liquid crystalline@hard capsules for sustained release of hydrophilic and hydrophobic drugs. Drug Deliv. 2020 Dec;27(1):449-59. doi: 10.1080/10717544.2020.1736210

22. Chaturvedi M, Kumar M, Pathak K, et al. Surface solid dispersion and solid dispersion of meloxicam: comparison and product development. Adv Pharm Bull. 2017 Dec;7(4):569-77. doi: 10.15171/apb.2017.068. Epub 2017 Dec 31.

23. Amelotex. Instructions for the use of the drug. Available from: https://www.rlsnet.ru/tn_index_id_40794.htm (accessed 02.10.2021) (In Russ.).

24. Novikova LB, Akopyan AP. Myofascial pain syndrome. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(10):21-4. doi: 10.17116/jnevro201511510121-24 (In Russ.).

25. Butin AA. Meloxicam injections for treatment of vertebral pains in neurological practice. Trudnyy patsiyent. 2011;9(11):20-3 (In Russ.).

26. Badalyan OL, Burd SG, Savenkov AA, et al. Possibilities of using Amelotex in diseases of the musculoskeletal system. RMJ. 2010;18(9):536-38 (In Russ.).

27. Eliseyev MS, Barskova VG, Vladimirov SA. Prospects for using injectable meloxicam (Amelotex®) in patients with osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2009;3(1):58-60. doi: 10.14412/1996-7012-2009-525 (In Russ.).

28. Eliseyev MS, Barskova VG, Vladimirov SA. Use of injectable meloxicam (Amelotex®) formulation in patients with gonarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2009

29. Eliseyev MS, Vladimirov SA. Use of meloxicam (Amelotex®) in patients with chronic gout to prevent. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2011;5(4):49-52 (In Russ.).

30. Loginova GV. Clinical efficacy of Amelotex® and CompligamB® in vertebrogenic lumboishalgia. Trudnyy patsiyent. 2010;8(3):25-8 (In Russ.).

31. Sinchenko OG. The combination of Amelotex and CompligamB drugs in the treatment of dorsopathy and arthralgia in patients with arterial hypertension. Trudnyy patsiyent. 2010;8(12):46-52 (In Russ.).

32. Shavlovskaya OA, Romanov ID. The assessment of efficacy and tolerability of the complex therapy of low back pain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):63-7. doi: 10.17116/jnevro202012007163 (In Russ.).

33. Dadasheva MN, Gorenkov RV, Zolotovskaya IA, Dadasheva KN. The assessment of the clinical efficacy and tolerability of complex treatment of patients with acute low-back pain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(9):47-52. doi: 10.17116/jnevro202012009147 (In Russ.).

34. Gorenkov RV, Dadasheva MN, Lebedeva DI, Choi IV. Pain reliever combinations in treatment of patients with acute musculoskeletal back pain. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):73-8. doi: 10.14412/2074-2711-2021-2-73-78 (In Russ.).

35. Shirokov VA, Potaturko AV, Terekhov NL. Nonsteroidal anti-inflammatory drugs, muscle relaxants, and B-group vitamins in the treatment of lumbar ischialgia. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(6):71-6. doi: 10.14412/2074-2711-2020-6-71-76 (In Russ.).

36. Zolotovskaia IA, Davydkin IL. Cognitivecytokine effect of nonsteroidal antiinflammatory drugs in the therapy of elderly patients with osteoarthritis. Uspekhi gerontologii = Adv geront. 2017;30(3):381-9 (In Russ.).